U.S. markets open in 1 hour 34 minutes
  • S&P Futures

    4,352.75
    -69.00 (-1.56%)
     
  • Dow Futures

    33,840.00
    -622.00 (-1.80%)
     
  • Nasdaq Futures

    15,112.25
    -213.75 (-1.39%)
     
  • Russell 2000 Futures

    2,179.70
    -48.60 (-2.18%)
     
  • Crude Oil

    70.34
    -1.63 (-2.26%)
     
  • Gold

    1,756.30
    +4.90 (+0.28%)
     
  • Silver

    22.33
    -0.01 (-0.05%)
     
  • EUR/USD

    1.1708
    -0.0023 (-0.20%)
     
  • 10-Yr Bond

    1.3700
    0.0000 (0.00%)
     
  • Vix

    25.82
    +7.13 (+38.15%)
     
  • GBP/USD

    1.3661
    -0.0077 (-0.56%)
     
  • USD/JPY

    109.5380
    -0.3570 (-0.32%)
     
  • BTC-USD

    43,576.11
    -3,786.68 (-8.00%)
     
  • CMC Crypto 200

    1,082.81
    -142.72 (-11.65%)
     
  • FTSE 100

    6,846.14
    -117.50 (-1.69%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Is BioHiTech Global, Inc. (NASDAQ:BHTG) Trading At A 48% Discount?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Does the July share price for BioHiTech Global, Inc. (NASDAQ:BHTG) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to their present value. This will be done using the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

Check out our latest analysis for BioHiTech Global

Is BioHiTech Global fairly valued?

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) forecast

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Levered FCF ($, Millions)

US$623.0k

US$2.74m

-US$25.6m

US$9.47m

US$9.40m

US$9.41m

US$9.47m

US$9.57m

US$9.70m

US$9.85m

Growth Rate Estimate Source

Analyst x1

Analyst x1

Analyst x1

Analyst x1

Est @ -0.74%

Est @ 0.08%

Est @ 0.65%

Est @ 1.05%

Est @ 1.33%

Est @ 1.53%

Present Value ($, Millions) Discounted @ 8.3%

US$0.6

US$2.3

-US$20.1

US$6.9

US$6.3

US$5.8

US$5.4

US$5.1

US$4.7

US$4.4

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$21m

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.0%. We discount the terminal cash flows to today's value at a cost of equity of 8.3%.

Terminal Value (TV)= FCF2031 × (1 + g) ÷ (r – g) = US$9.8m× (1 + 2.0%) ÷ (8.3%– 2.0%) = US$159m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$159m÷ ( 1 + 8.3%)10= US$71m

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$92m. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of US$1.7, the company appears quite good value at a 48% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

dcf
dcf

The assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at BioHiTech Global as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.3%, which is based on a levered beta of 1.340. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Looking Ahead:

Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Why is the intrinsic value higher than the current share price? For BioHiTech Global, there are three further elements you should further research:

  1. Risks: To that end, you should learn about the 5 warning signs we've spotted with BioHiTech Global (including 1 which is a bit concerning) .

  2. Future Earnings: How does BHTG's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.